Survivin、FAS在膀胱移行细胞癌中的表达及临床意义  

Expression and clinical significance of Survivin and FAS in bladder transitional cell carcinoma

作　　者：周健[1] 李海[2] 陈金珍[2] 黄振华[1] 

机构地区：[1]昆山市第一人民医院泌尿外科,江苏昆山215300 [2]昆山市第一人民医院病理科,江苏昆山215300

出　　处：《诊断学理论与实践》2009年第6期627-630,共4页Journal of Diagnostics Concepts & Practice

摘　　要：目的:通过检测Survivin、FAS在膀胱移行细胞癌中的表达,分析其与膀胱癌临床病理指标的关系,并研究两者表达的相关性。方法:采用免疫组织化学S-P法,检测Survivin、FAS在49例膀胱移行细胞癌和11例膀胱炎标本中的表达情况。结果:Survivin和FAS在膀胱移行细胞癌中的阳性表达率分别为69.4%(34/49)、38.8%(19/49),在膀胱炎中的阳性表达率分别为0%(0/11)、100%(11/11),Survivin和FAS在不同膀胱组织中的阳性表达相比有显著差异(P<0.01,P<0.01);Survivin的表达与肿瘤的病理分级、临床分期关系密切(P<0.05,P<0.05),FAS的表达与肿瘤临床分期关系密切(P<0.05);Survivin的表达与FAS的表达呈负相关(r=-0.289,P<0.05)。结论:Survivin的高表达和FAS的低表达对膀胱移行细胞癌早期诊断具有意义,在膀胱癌发生发展过程中,两者可能通过共同通路发挥协同作用。Objective To investigate the expression of Survivin and FAS in bladder transitional cell carcinoma （BTCC） as well as the correlation between their expression and clinical pathological characteristics and the correlation between these two factors. Methods Immunohistochemical S-P staining method was adopted for detecting the expression of Survivin and FA S in 49 cases of BTCC and 11 cases of cystitis. Results The positive expression rate of survivin in BTCC（69.4%,34/49） was significantly higher than that in cystitis（0%,0/11）（P〈0.01）, and the positive expression rate of FAS in BTCC（38.8%,19/49） was significantly lower than that in cystitis（100%,11/11）（P〈0.01）.The expression of survivin was correlated with tumor grade and clinical stage （P〈0.05, P〈0.05）, and the expression of FA S was correlated with the clinical stage（P〈0.05）. Spearman correlation analysis showed that there was a negative correlation between the expression of Survivin and FAS（r= -0.289,P〈0.05）. Conclusions High positive expression of Survivin and low positive expression of FAS suggested that these two factors could be used for the early diagnosis of BTCC. These two factors might display their synergistic action through a common pathway in the development and progression of BTCC.

关 键 词：膀胱移行细胞癌 SURVIVIN FAS 免疫组化 

分 类 号：R737.14[医药卫生—肿瘤]